-

Bio-Rad to Participate in Fireside Chat During 2023 RBC Capital Markets Global Healthcare Conference

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during the 2023 RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 3:35 PM Eastern Time (12:35 PM Pacific Time).

A live webcast and subsequent replay of the event will be available in the Investor Relations section of Bio-Rad’s website at bio-rad.com.

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostics markets. With focus on quality and customer service for over 70 years, our products advance scientific discovery and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with approximately 8,300 employees worldwide and 2022 revenues of $2.8 billion. For more information, please visit bio-rad.com.

Contacts

Investor Contact:
Edward Chung, Investor Relations
510-741-6104
ir@bio-rad.com

Media Contact:
Anna Gralinska, Corporate Communications
510-741-6643
cc@bio-rad.com

Bio-Rad Laboratories, Inc.

NYSE:BIO

Release Versions

Contacts

Investor Contact:
Edward Chung, Investor Relations
510-741-6104
ir@bio-rad.com

Media Contact:
Anna Gralinska, Corporate Communications
510-741-6643
cc@bio-rad.com

More News From Bio-Rad Laboratories, Inc.

Bio-Rad Reports Second-Quarter 2026 Financial Results

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2026. Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: “Second-quarter reported revenue was flat year-over-year, with growth in Clinical Diagnostics offset by continued softness in Life Science. Despite Life Science headwinds, our digital PCR...

Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the second quarter of 2026 on Tuesday, August 4, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day. To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U...

Bio-Rad to Participate in Upcoming Investor Conferences

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company will participate in the following upcoming investor conferences: 2026 RBC Capital Markets Global Healthcare Conference Format: Fireside chat and one-on-one investor meetings Participants: Roop K. Lakkaraju, Chief Financial Officer Date and Time: Tuesday, May 19, 2026, at 8:30 AM Eastern Time; a live webc...
Back to Newsroom